Research and Markets: Biosimilars: A Physician's Perspective

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/55d346/biosimilars_a_phy) has announced the addition of the "Biosimilars: A Physician's Perspective" report to their offering.

To say the environment around biosimilars is fluid would be an understatement. With fluidity comes uncertainty and with uncertainly comes opportunity. Many industry pundits are evaluating the biosimilar market by taking a big picture, macro assessment of the regulatory, clinical development, and commercialization issues. Industry Standard Research (ISR) took a focused approach to answering a few pointed questions around the potential prescribing of biosimilars. The publisher took this approach because of the fluid nature of the environment and because regardless of the nascent legislation recently enacted in the United States, or the forthcoming plan from the FDA, and the relative low adoption of biosimilars in Europe; they believe that physicians/prescribers will be at the strategic center of biosimilar success or failure.

Key Topics Covered:

  • Clinical trial expectations
  • Price expectations
  • Adoption expectations
  • Safety and Efficacy expectations from Innovator and Generic manufacturers

For more information visit http://www.researchandmarkets.com/research/55d346/biosimilars_a_phy



CONTACT:

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
[email protected]

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Biotechnology

MEDIA:

Logo
 Logo

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.